Our new AI assistant can help patients, caregivers, and researchers find important information faster. Click the logo in the lower right corner to try it.
Kurt Losert 
For patients and families considering clinical trials, understanding the treatment approach and the thinking behind a study can be an important first step. We’re pleased to share a video featuring Dr. Marina Baretti of Johns Hopkins, who provides an overview of the quadruple immune therapy clinical trial now underway at the Sidney Kimmel Comprehensive Cancer …
Yesterday, Stone Point Capital once again brought together friends, colleagues, sponsors, and supporters for its annual Charity Golf Tournament benefiting the Fibrolamellar Cancer Foundation. For our community, this event represents far more than a day of golf. Since 2009, Stone Point Capital has dedicated the proceeds from its annual tournament to FCF, providing extraordinary and …
The U.S. Department of Defense has asked FCF to help to recruit community members to serve as consumer reviewers for the Peer Reviewed Cancer Research Program …
FCF congratulates Ilaria Gritti, PhD, on receiving an NCI K99/R00 Pathway to Independence Award, a prestigious career-development award that helps promising postdoctoral researchers transition to independent research careers. Ilaria Gritti, a postdoctoral fellow in Nabeel Bardeesy’s laboratory at Massachusetts General Hospital, studies the biology of fibrolamellar carcinoma (FLC). Her new award will support research investigating …
The Fibrolamellar Cancer Foundation has awarded a new research grant to Paul Thomas, PhD, of the Fred Hutchinson Cancer Center in Seattle, Washington to advance the development of T-cell receptor-engineered T-cell (TCR-T) therapies for fibrolamellar carcinoma (FLC). FLC is driven by the DNAJB1-PRKACA fusion protein, a unique cancer-specific target that is absent from healthy cells. …
For patients and families affected by fibrolamellar cancer (FLC), hope is built through progress. Every discovery, every research collaboration, and every clinical trial brings us closer to better treatments for this devastating disease. Today, that progress is becoming increasingly tangible. Researchers are translating laboratory discoveries into clinical trials that offer new treatment opportunities for people …
A clinical trial of a new combination immune therapy specifically designed for fibrolamellar carcinoma (FLC) is beginning at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University (Baltimore, MD). The study is led by Drs. Marina Baretti and Mark Yarchoan. Importantly, this trial builds directly on findings from earlier studies that demonstrated the promise …
The Fibrolamellar Cancer Foundation (FCF) has awarded a new research grant to investigators at the Icahn School of Medicine at Mount Sinai in New York City. Research has identified SLC16A14 as one of the most highly upregulated genes in FLC, making it a potential candidate for therapeutic development. However, much remains unknown about SLC16A14’s biological …
FCF is please to announce that it has awarded a new grant to Mark Yarchoan, MD, and Waqar Arif, MD, of Johns Hopkins University to identify actionable antibody-drug conjugate targets in FLC. Antibody-drug conjugates (ADCs) are an emerging class of targeted cancer therapies sometimes described as “smart chemotherapy.” They combine an antibody that recognizes a …